An Open-Label Phase 1 Study to Investigate the Safety and Efficacy of CYP-001 for the Treatment of Adults With Steroid-Resistant Acute Graft Versus Host Disease

Trial Profile

An Open-Label Phase 1 Study to Investigate the Safety and Efficacy of CYP-001 for the Treatment of Adults With Steroid-Resistant Acute Graft Versus Host Disease

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Aug 2018

At a glance

  • Drugs CYP 001 (Primary)
  • Indications Graft-versus-host disease
  • Focus Adverse reactions
  • Sponsors Cynata Therapeutics
  • Most Recent Events

    • 30 Aug 2018 Results published in the Cynata Therapeutics Media Release
    • 21 Jun 2018 According to a Cynata Therapeutics media release, The Primary Evaluation Period will be completed when the final patient in Cohort B reaches 100 days after the first infusion of CYP-001. The company announce Day 100 Cohort B data once an analysis has been completed.
    • 21 Jun 2018 Data from a day 28 analysis of patients in Cohort B (n=8) published in the Cynata Therapeutics Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top